Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

By Ralph DeFronzo, R. Ratner, Jenny Han, Dennis D. Kim, M. Fineman, A. Baron. Diabetes Care, 2005

1,627 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c013f4619f1de5708ee1d4da2c4c866f0ae11efe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. (2007, result): “We noted small baseline differences in only 3 studies.(11,12,18) Participant withdrawal was approximately 19% in the GLP-1 analogue studies (19% with exenatide and 12% with liraglutide) and 18% in the DPP4 inhibitor studies (20% with sitagliptin and 16% with vildagliptin).”
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus (2006, background): “Improvements in beta cell function have also been observed with exenatide and vildagliptin in patients with type 2 diabetes [11–14].”
Incretin-based therapies for type 2 diabetes mellitus (2009, background): “Three pivotal, phase III clinical trials, each of 30 weeks duration, examined the efficacy of twice-daily injections of 5 µg or 10 µg exenatide in individuals who had T2DM that was inadequately controlled with a sulfonylurea and/or metformin”
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008, neutral): “It is not associated with hypoglycaemia, but causes a relatively high frequency of gastrointestinal disturbances, with 30–45% of treated patients experiencing one or more episodes of nausea, vomiting or diarrhoea [78–81].”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “…presence did not seem to impact the degree of glycemic control, and 2), increasing titer of antibody also did not seem to be reflected in worsening blood glucose control (Buse et al., 2004; DeFronzo et al., 2005; Heine et al., 2005; Kendall et al., 2005; Nauck et al., 2007a; Zinman et al., 2007).”